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Abstract
We report a 49-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological com-
plete response after neoadjuvant chemotherapy with trastuzumab-containing regimen. He underwent esophago-
gastroduodenoscopy in September 2009, which revealed a 2-cm gastric ulcer on the lesser curvature proximal to
angularis. Biopsy of gastric ulcer showed moderately differentiated adenocarcinoma with overexpression of human
epidermal growth factor receptor 2 (HER2) by immunohistochemistry and fluorescence in situ hybridization. Further
workups with endoscopic ultrasound, computed tomography and positron emission tomography staged his cancer
as T3N1M0. He received 3 cycles of neoadjuvant chemotherapy consisting of trastuzumab, oxaliplatin, docetaxel
and capecitabine without severe toxicities except grade 2 diarrhea near the completion of cycle 3 requiring dis-
continuation of capecitabine. Afterwards, he received total gastrectomy with extended D2 lymph node dissections
showing pathological complete response. He went on to receive 3 more cycles of chemotherapy postoperatively.
The role of trastuzumab as a part of perioperative therapy in gastric cancer overexpressing HER2 is worth further
investigation.
Introduction
Gastric cancer is the fourth most common cancer
worldwide, with overall 5-year survival rate of approxi-
mate 20%, representing a significant challenge for the
treating physicians [1]. Perioperative chemotherapy has
been shown to cause tumor downstaging and improve
survival in patients with resectable gastric cancer [2].
Response to neoadjuvant treatment is the most impor-
tant predictor of survival after curative resection of gas-
tric cancer [3-5].
In this case report, we describe a case of pathological
complete response after neoadjuvant chemotherapy with
trastuzumab-containing regimen in gastric cancer. We
discuss histopathological findings and review the perti-
nent literatures.
Case report
A 49-year-old Chinese male with gastroesophageal
reflux disease and H. Pylori infection underwent esopha-
gogastroduodenoscopy (EGD) in September 2009, which
revealed a 2-cm gastric ulcer on the lesser curvature
proximal to angularis. Biopsy of gastric ulcer showed
moderately differentiated adenocarcinoma. Tumor ana-
lysis for human epidermal growth factor receptor 2
(HER2) was performed by HercepTest (Genzyme, Los
Angeles, CA) indicating 3+ immunohistochemistry
(IHC) staining (Fig. 1). HER2 gene amplification was
confirmed by fluorescence in situ hybridization (FISH)
demonstrating HER2/CEP17 (chromosome enumeration
probe 17) ratio of 4. Endoscopic ultrasound study indi-
cated presence of perigastric lymphadenopathy and
tumor invading through the muscularis propria. Other
staging workups, including computed tomography (CT)
scan of chest, abdomen and pelvis and positron emis-
sion tomography-CT (PET-CT) scan, did not reveal any
distant metastasis. The clinical staging was T3N1M0,
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chemotherapy before definitive surgery. The information
of ToGA trial was presented to patient [6], and patient
agreed to receive trastuzumab-containing regimen: tras-
tuzumab 6 mg/kg iv on day 1, oxaliplatin 130 mg/m
2 iv
on day 1, docetaxel 30 mg/m
2 iv on day 1 and day 8,
and capecitabine 625 mg/m
2 po bid on day 1 to day 21,
every 3 weeks. He received 3 cycles chemotherapy with-
out severe toxicities except grade 2 diarrhea near the
completion of cycle 3 requiring discontinuation of cape-
citabine. The post-treatment imaging studies including
CT scan of chest, abdomen and pelvis and PET-CT scan
showed persistent mild FDG [fluorodeoxyglucose (18F)]
activity involving the stomach without identifiable mass
or distant metastasis.
In January 2010, he received total gastrectomy with
extended D2 lymph node dissections, Roux-en-Y eso-
phagojejunostomy and cholecystectomy. Prior to surgical
resection, the intraoperative EGD showed a healed scar
in the original ulcerative tumor site, and laparoscopy
revealed no evidence of peritoneal carcinomatosis or
metastatic implants. Pathological examination of the
surgical specimen indicated no residual adenocarcinoma
but scar on lesser curvature with fibrosis extending into
muscularis propria (Fig. 2). There were no tumor identi-
fied in 44 perigastric lymph nodes and 2 lymph nodes
from porta hepatis. He recovered uneventfully after sur-
gery, and received 3 more cycles of chemotherapy with
the same regimen with dose reduction on docetaxel and
capecitabine due to gastrointestinal toxicities. He has
remained free of disease after completion of
chemotherapy.
Discussion
HER2 exhibits tyrosine kinase activity and functions as a
growth factor receptor [7]. HER2 overexpression due to
gene amplification in gastric cancer has led to aggressive
clinical course and poor prognosis [8]. Trastuzumab, a
monoclonal antibody against HER2, causes cell cycle
arrest at G1 and exhibits antitumor activity in HER2
overexpressed gastric cancer cells [9,10]. Additionally,
trastuzumab can enhance cytotoxic effects of che-
motherapy in gastric cancer xenograft overexpressing
HER2, when combined with capecitabine, cisplatin, or
taxane [11]. Phase II studies incorporating trastuzumab
with cisplatin-based regimen in patients with advanced
gastric cancer overexpressing HER2 have demonstrated
promising activities [12,13].
The ToGA study presented at 2009 annual meeting of
American Society of Clinical Oncology has screened
about 3,800 patients with advanced gastric cancer from
24 countries [14]. HER2 overexpression was detected in
22%, and the concordance rate between IHC and FISH
was high at all levels of HER2 positivity [15]. There was
a specific pattern of disease which correlated with HER2
overexpression. Higher rates occurred in intestinal and
proximal or gastroesophageal junction cancers than in
diffuse or distal gastric cancers.
Five hundred and eighty four patients tested positive
for HER2 overexpression (IHC 3+ and/or FISH positive)
were enrolled into ToGA study, a phase III trial com-
paring fluoropyrimidine (5-fluorouracil [5-FU] or capeci-
tabine) and cisplatin chemotherapy with or without
trastuzumab. Patients who received trastuzumab plus
Figure 1 Immunohistochemical study of HER2 protein in
biopsied specimen before chemotherapy. The moderately
differentiated adenocarcinoma cells infiltrated the gastric
submucosa and overexpressed HER2 (3+ by HercepTest) on the cell
membrane (immunoperoxidase stain, 200×).
Figure 2 Microscopic finding of the resected specimen after
chemotherapy. No residual adenocarcinoma was found in the
original ulcerated adenocarcinoma site on lesser curvature. Instead,
it was completely replaced by dense fibrous tissue with partial
re-epithelialization of the overlying mucosal surface and fibrosis
extending into muscularis propria (hematoxylin and eosin stain,
100×).
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months vs. 11.1 months, P = 0.0046), longer progres-
sion-free survival (6.7 months vs. 5.5 months, P =
0.0002), and higher response rates (47% vs. 35%, P =
0.0017) than those who received chemotherapy alone.
Complete response was noted in 5.4% of patients receiv-
ing trastuzumab plus chemotherapy vs. 2.4% in che-
motherapy alone. There were no significant differences
in the toxicities between these two groups. This study
has established a new paradigm using trastuzumab in
combination with chemotherapy in patients with
advanced gastric cancer overexpressing HER2.
MAGIC trial for investigation of perioperative che-
motherapy was conducted in patients with resectable
adenocarcinoma of stomach, gastroesophageal junction
or distal esophagus [2]. Five hundred and three patients
were randomly assigned to either perioperative che-
motherapy with epirubicin, cisplatin and infusional 5-FU
(ECF) and surgery or surgery alone. Despite of only 43%
of patients completing the planned 6 cycles of che-
motherapy (3 cycles before surgery and 3 cycles after-
wards), there was statistically significant improvement in
overall survival in patients receiving chemotherapy and
surgery (5-year survival: 36% for chemotherapy plus sur-
gery vs. 23% for surgery). At the time of surgery, the
patients receiving preoperative chemotherapy had signif-
icantly smaller tumor size and lower stage. However,
there was no pathological complete response in patients
receiving preoperative ECF in this study.
The infusional 5-FU in the ECF regimen is given con-
tinuously through a venous access device, and is asso-
ciated with inconvenience and higher incidence of
thrombosis and infection. Furthermore, cisplatin can
cause nephrotoxicity, ototoxicity, and severe emesis.
REAL-2, a randomized study in patients with advanced
gastroesophageal cancer using two-by-two design, has
shown 5-FU can be replaced by capecitabine, and cispla-
tin by oxaliplatin in the regimen of ECF without affect-
ing the efficacy [16].
Docetaxel has demonstrated encouraging activity in
the treatment of advanced gastric cancer [17]. Phase II/
III trial V325 has shown adding docetaxel to cisplatin
and 5-FU (DCF) significantly improved time to tumor
progression, survival, and response rate in advanced gas-
tric cancer patients receiving first-line treatment [18].
Based on results of this study, Food and Drug Adminis-
tration of U.S.A. approved DCF for the treatment of
advanced gastric cancer in 2006. Various modifications
of DCF with the intent to improve tolerability have been
developed. Replacing cisplatin by oxaliplatin and 5-FU
by capecitabine, the combination of docetaxel, oxalipla-
tin and capecitabine have demonstrated encouraging
activity and good tolerability in early-phase studies
[19,20].
The administration of trastuzumab can result in sub-
clinical and clinical cardiac failure, and the incidence is
much higher in patients receiving trastuzumab concur-
rently with anthracycline-containing chemotherapy regi-
mens [21]. Instead of using ECF, we decided to use
docetaxel, oxaliplatin and capecitabine in combination
with trastuzumab as perioperative chemotherapy for our
patient mainly due to the concern of cardiac toxicity.
We have monitored our patient’s cardiac function with
periodic echocardiogram evaluation, and find no evi-
dence of cardiac failure.
Our case illustrates the first reported case of patholo-
gical complete response after neoadjuvant chemotherapy
with trastuzumab-containing regimen in a patient with
locally advanced gastric cancer overexpressing HER2.
The use of docetaxel, oxaliplatin and capecitabine in
combination with trastuzumab in this setting remains
experimental, and ideally should be considered only in
the context of a clinical trial. Therefore, the role of tras-
tuzumab as a part of perioperative therapy is worth
further investigation.
Consent
Written informed consent was obtained from each
patient for publication of this case report and accompa-
nying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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